Eureka Biotechnology Co., Limited

🌿 Proud moment for EurekaBio: We've secured a silver certification in the 2024 EcoVadis CSR rating! Discover our journey to the top 5%! 🌟 We're excited to share that EurekaBio has earned a silver certification in the 2024 EcoVadis social responsibility rating, placing us in the top 15% of all evaluated companies and the top 5% in our industry. This accolade highlights our excellence in corporate social responsibility and sustainable development. EcoVadis, a global leader in CSR ratings, assessed our performance across 21 indicators in four key areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. At EurekaBio, we prioritize CSR and sustainable practices to support innovative therapies, enhance patient access, and address unmet medical needs. Our commitment to continuous improvement drives us to create lasting value for society, the environment, and our company, advancing biotechnology and treatment frontiers.

Unlock the future of biotech with cost-saving innovations—meet us at Booth #33 at the CAR-TCR Summit in Boston! 🚀 From September 18-19, our Director of Business Development, Vikki MI, will be at Booth #33. Discover our latest innovations that can cut your viral vector production costs by 80% and explore our fully automated cell processing system. Don't miss this opportunity to see how we can transform your operations. Visit us and learn more!

Discover how closed, automated cell processing systems are revolutionizing cell therapy—read our case study now! 🚀🔬 The cell therapy drug market is witnessing unprecedented growth, driven by relentless technological advancements and expanding clinical applications. This surge has introduced numerous groundbreaking therapies to the public. However, this booming sector faces significant challenges. The high personalization and complexity of cell therapy products lead to steep production costs, pushing companies to develop cost-effective manufacturing processes without compromising therapeutic efficacy. Additionally, stringent regulatory frameworks demand exceptional safety and consistency, as even minor contaminations or variations can jeopardize treatment outcomes and patient safety. Furthermore, the industry grapples with a shortage of skilled professionals and the high costs associated with their training. Amid these challenges, fully closed, automated cell processing systems present a vital solution for cell therapy companies, enabling them to overcome obstacles and drive industry progress. Interested in how you can use a closed, automated cell processing system for PBMC separation? Click the link to explore our Case Study https://lnkd.in/g5Vqp-v6

Here's a quick peek 👀 of how we celebrate our unique culture at EurekaBio:   At EurekaBio, we believe in celebrating not just our achievements, but also our journey. This year marks a decade of innovation and growth, and we're thrilled to share a special tradition we've cultivated - 'Lychee Day'. 🍇   Lychee Day isn't just about taking a time off and enjoying the delicious fruit. It's about taking a step back to appreciate our collective efforts, fostering team spirit, and recognizing the unique contributions of each member. Over the years, this day has become a symbol of our unity and our commitment to creating a vibrant work culture.   Whether it's through fun activities, team-building exercises, or simply sharing stories and laughs, Lychee Day has become a cherished part of EurekaBio's identity. It reminds us that our strength lies in our people and the bonds we form.   Celebrating Lychee Day is more than a tradition; it's a testament to our values and the people who make EurekaBio exceptional.   How do you celebrate your company's culture? Share your unique traditions in the comments below! 🚀   #CompanyCulture #TeamSpirit #EurekaBio #LycheeDay

Here's a super simple tip that helps us achieve breakthroughs in biotech: EuLV™ is revolutionizing viral vector production, offering unprecedented efficiency, quality and scalability. As the biotech landscape evolves, it's crucial to stay ahead with cutting-edge solutions. Our CMO Roy LIU will be at BPD from 8th-10th August to discuss how EuLV™ can transform your production processes. Plus, we're excited to announce a new project launching soon, designed to help more biotech companies experience the benefits of this groundbreaking technology! 🚀 Don't miss the chance to connect and explore how EuLV™ can elevate your operations. Looking forward to meeting and brainstorming innovative ideas together! Let's elevate biotech—one vector at a time. Comment below or message me to set up a meeting!

Unlock the future of cell & gene therapy with the EuLV™ System—achieve viral vector titers like never before! 🚀 #Biotech #Innovation #EuLV Discover the impressive capabilities of the EuLV™ System in generating high-titer, high-quality lentiviral vectors. Our application note demonstrates that the AntiCD19-CAR producer cell line, utilizing the EuLV™ System, easily achieved lentivirus titers of 8.13E10 TU/L in a 1L wave bioreactor before purification. Ready to elevate your viral vector production to this level? Contact us for a personalized consultation and take your cell & gene therapy projects to new heights! Explore more on https://lnkd.in/gBEaxrcN

Discover how we slashed lentiviral vector production costs by 80% without compromising quality! 🚀 #BiotechInnovation We use real-world customer case data to illustrate the development of the stable producer cell line and how this system reduces the cost of LVV production. We successfully delivered the stable producer cell line integrated with the client’s GOI and facilitated the client in implementing a 25L suspension-mode lentiviral vector production system using the EuLV™ stable producer cell line. This new system slashed the materials costs for lentiviral vector production by 10-fold without compromising quality. The higher titers achieved per batch with the EuLV™ stable producer cell line system also led to a reduction in batch runs, further lowering the manufacturing costs of lentiviral vectors for CAR-T therapies... Head over to our website for the full case study https://lnkd.in/gnKtjeju Interested in learning how we can help you achieve similar results? Let's connect and discuss how our innovative solutions can transform your production process! 🤝#EuLV #ConnectWithU

Join us at BIO 2024 in San Diego! Our Director of Business Development, Vikki, will be available all week to discuss how you can slash up to 80% off your viral vector production costs. Vikki is excited to share groundbreaking strategies for cost-effective viral vector production. Discover innovative solutions and stay at the forefront of biotech advancements. Don't miss this opportunity to gain valuable insights! 🤝 #EuLV #BIO2024

Heading to ISCT 2024? Come and let's talk about why you don't have to choose between reducing cost (by 80%) and high titer on your lentiviral vector production.

Our CEO Marl Ma and CMO Roy Liu are at Baltimore , booth 2159. Talk to us!